[State of intestinal microbiota in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease].

High prevalence of type 2 diabetes mellitus (DM) and nonalcoholic fatty liver disease (NAFLD) contributes to the intensification of scientific research the aim of which is to improve existing treatment. It is given the data about the state of intestinal microbiota in 64 patients with type 2 DM and NAFLD, 26 patients with type 2 DM and 28--with NAFLD. The research revealed significant changes in microbiota composition in patients with type 2 DM combined with NAFLD. Decompensated dysbiosis was registered in 71.9% of patients in this group which manifested in increased quantitative indicators of transient microflora crop with pathogenic characteristics and lack of microflora with protective characteristics.

[Correlation of adiponectin in patients with type 2 diabetes with nonalcoholic fatty liver disease depending on transaminases level].

We studied the changes of serum adiponectin and it correlations in patients with type 2 diabetes (T2D) and NAFLD related to transaminases levels. Serum adiponectin levels were significantly lower in the increased ALT group than in the normal ALT and control group. After adjusting for age, sex, and adiposity adiponectin was significantly correlated in control group with fasting insulin, and insulin resistance by homeostasis model of assessment (HOMA-IR); in the normal ALT group with HDL-cholesterol , triglycerides, fasting insulin and HOMA-IR; in the elevated transaminases group with ALT, fasting insulin and HOMA-IR. Step-wise multiple linear regression analyses demonstrated that in NAFLD with normaltransaminases, independent predictors of adiponectin was HOMA-IR, triglycerides, BMI and duration of T2D. In NAFLD with elevated transaminases, adiponectin was associated with HOMA-IR, BMI, male genderand ALT.

[Effect of probiotics on proinflammatory cytokines level in patients with type 2 diabetes and nonalcoholic fatty liver disease].

We examined 72 patients with T2D and NAFLD. All patients divided by us on the way of therapy into 2 groups. The main group (n = 45) received oral antidiabetic therapy and multiprobiotic "Symbiter" within 30 days. Patients of comparison group (n = 27) received only hypoglycemic drugs. Also in each group we identified patients with normal and elevated level of transaminases. We observed 1.5-2 times increasing of cytokines in patients with NAFLD and elevated transaminase levels compared to patients with normal transaminase levels. We noted statistically significant reduction of proinflammatory cytokines in plasma, after 30 days of therapy, in patients with elevated levels of transaminases. In particular, the level of IL-6 decreased on 30.9% (P < 0.001), IL-8 - 19.9% (P = 0.001), TNF-alpha - 13.4% (P < 0.001), IL-1beta - 17.9% (P < 0.001) and IFN-gamma on 18.7% (P < 0.001) respectively. In patients with normal levels transaminases and NAFLD were significantly decreased only TNF-alpha on 15.1% (P = 0.003) and IL-8 on 15.2% (P = 0.017). Significant changes in cytokines levels in patients of comparative group we don't observed. Probiotics can be recommended for use in patients with different stages of NAFLD and T2D as an adjunct to standard treatment regimens because it decreases manifestations of low-grade systemic inflammatory response.

[Liver stiffness in animals with glutamate-induced obesity (according to shear wave ultrasound elastography)].

We studied changes of liver stiffness measured by SWE in animals with glutamate-induced obesity (GIO). We noted significant increase of LS on 63.6% compared to intact rats (P < 0.001). Histologically confirmed non-alcoholic steatosis diagnosed in 93.3% of animals with obesity. The AUROC of SWE for in animals with GIO was 0.983 (95% CI 0.955-0.999; P < 0.001). The optimal LS cutoff point for the prediction of steatosis were > 6.25 kPa, with sensitivity, specificity, PPV and NPV 86.6; 100; 100 and 93.7% respectively.

[Phytoconcentrates "dzherelo" and "lizorm" in therapy of autoimmune thyroiditis]. / Fitokontsentraty "dzherelo" ta "lizorm" v likuvanni autoimunnoho tyreoïdytu.

Treatment of patients with autoimmune thyroiditis with phytoconcentrates dzherelo and lizorm has been shown to improve the patients general well-being, alleviate gross manifestations of the condition, impede the development of the autoimmune process. The above therapy is well-tolerated, has no hepato-/nephrotoxic effect, causes no functional/structural disturbances, and does not affect the sizes of the thyroid gland. The phytoconcentrates dzherelo and lizorm can be recommended as treatment of autoimmune thyroiditis (euthyroid state, mild hypothyroisis, in those settings where activity of the autoimmune process is not very high.

[Iodine deficiency disorders--a present medical and social problem]. / Iododefitsytni rozlady--aktual'na medyko-sotsial'na problema.

The article presents data by foreign authors and those in our country who substantiate the urgency of the problem of iodine deficiency disorders, diagnosis and prophylaxis thereof.

[Characteristics of the therapy of patients with type II diabetes mellitus and metabolic syndrome]. / Osoblyvosti terapiï khvorykh na tsukrovyi diabet II typu z metabolichnym syndromom.

The article focuses on the action of sugar-lowering drugs of different groups (metformin, acarbose, gliquidone, diacamf, food fibre, in patients with type II diabetes mellitus presenting with the metabolic syndrome. All studied medicinal agents compensated the carbohydrate and lipid metabolism, lowered the body mass, delayed the development of atherosclerosis, which facts were found to alleviate the manifestations of the metabolic syndrome.

[Phytopreparation Diabetin in treatment of patients with insulin-independent diabetes mellitus]. / Fitopreparat "Diabetyn" v likuvanni khvorykh z insulinonezalezhnym tsukrovym diabetom.

The phytopreparation "Diabetin" has a sugar-reducing, anorexigenic effects, facilitates loss of flesh lowering the body mass, causes the manifestations of diabetic angio- and neuropathies to delay. It is recommended as treatment of a mild form of diabetes as monotherapy or in moderately severe course of the trouble it can be used in combination with other peroral sugar-lowering drug preparations.

[The use of Doppler echography in the diagnosis of diffuse toxic goiter]. / Zastosuvannia ekhodopplerohrafiï v diahnostytsi dyfuznoho toksychnoho zoba.

Echodopplerography demonstrated a significant increase in the velocities of bloodflow and indices for the thyroid gland in diffuse toxic goiter. The presence of the increased velocity indexes and coefficients during remission permits predicting recurrent course of the affliction.

[Laser therapy in diabetes mellitus]. / Lazeroterapiia pry tsukrovomu diabeti.

Diabetic patients have been shown to derive great benefit from treatment with laser therapy as evidenced by experience gained with its use over many years. Laser therapy promotes compensation, has an antiatherogenic, antioxidant, immunomodulating effects, improves microcirculation, myocardial contractility and performance capability.

[Glucobay in the therapy of patients with non-insulin-dependent diabetes mellitus]. / Hliukobai v terapiï khvorykh na insulinonezalezhnyi tsukrovyi diabet.

The article focuses on the action of a new sugar-lowering drug preparation glucobai (acarbose) in 47 patients with non-insulin-dependent diabetes mellitus (NIDM). The drug was prescribed at a dose of 150-300 mg daily with meal. A marked sugar-lowering effect was manifested by reduction of the level of postprandial hyperglycemia, glycosylated hemoglobin, fructosamine, body mass of the patients. The results obtained permit recommending glucobai (acarbose) as a sugar-lowering drug in NIDM patients.

[The clinical efficacy of Vuglesorb enterosorbent in diabetic patients]. / Klinichna efektyvnist' enterosorbenta "Vuhlesorb" u khvorykh na tsukrovyi diabet.

Carbonic fibrous enterosorbent "Vuglesorb" used as a part of complex anti-diabetic treatment contributes to normalization of metabolism, promotes liquidation of ketoacidosis and principal morbid manifestations. Alongside with this, glycaemia and fructosamine blood level come to the norm. Marked anti-atherogenic effect was also observed. The drug is recommended for the treatment of patients with diabetes mellitus.